Non Small Cell Lung Cancer Clinical Trial
Official title:
Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial
2.5 Rationale for preoperative erlotinib therapy
Erlotinib is the only EFGR tyrosine kinase inhibitor to demonstrate a survival advantage and
symptom improvement in a large phase III trial after failure of chemotherapy in advanced
non-small cell lung cancer (Shepherd, Rodrigues Pereira et al. 2005). Although the potential
utility of erlotinib in earlier stage NSCLC is unclear, given its activity in advanced
disease and its minimal toxicity profile, there is likely a subset of patients who may
benefit and potentially be cured by adjuvant erlotinib therapy. Erlotinib may also have
greater antitumour activity in earlier stage disease. Therefore, we propose a phase II study
to assess erlotinib pre-operatively in clinical stage 1 and 2 NSCLC, and downstream effects
on signal transduction pathways and possible markers of treatment resistance and sensitivity.
The proposed study involves administering oral erlotinib for four weeks (28 days)
preoperatively in early stage (1A/B, 2A/B) NSCLC. Current waiting times for surgical
resection of early stage NSCLC at UHN ranges from 4 to 6 weeks (Hui, Johnston et al. 2004),
thus patients would not experience significant delay in time to surgery through this trial
design. This study provides the opportunity to explore the impact of erlotinib on early stage
NSCLC in humans, with pharmacodynamic assessment expected in 100% of patients post-treatment,
in addition to correlative imaging. This study will evaluate the feasibility of preoperative
therapy with erlotinib, and may facilitate the identification of predictive markers for
response to erlotinib in early stage NSCLC. This may help further define the subset of
patients who would benefit from adjuvant EGFR tyrosine kinase inhibitors, and those who may
require other adjuvant approaches including chemotherapy and further clinical trials.
Treatment will be administered on an outpatient basis. Patients may be identified by thoracic
surgeons, respirologists and/or interventional chest radiologists for study participation
upon clinical and radiographic assessment.
4.2 Diagnostic biopsy, Pretreatment Investigations
If patients have already had a core or FNA biopsy before referral, this material will be
sought from the original pathologist for review and inclusion in the study with appropriate
consent sought. If a patient does not have a biopsy upon presentation to the thoracic
surgeon, and consents to inclusion in the trial, a percutaneous biopsy will be mandated as
part of entry into the study. The order of test will be up to the treating thoracic surgeon.
As part of this procedure a large localizing needle is inserted into the tumour. In
collaboration with pathology, a fine needle is passed through the outer needle and an
immediate diagnosis will be made at the time of fine needle aspiration biopsy. After a
pathologic diagnosis of cancer is confirmed, additional biopsies to obtain material for
correlative studies will be performed through the standard localizing needle, assuming no
complications or technical difficulties have arisen. These studies will be done in
collaboration with thoracic interventional radiologists from Diagnostic Imaging, who perform
the lung fine needle aspirates and biopsies.
All patients will undergo pre-study assessments for symptoms, performance status,
radiographic assessment and blood tests (complete blood count, electrolytes, liver and renal
function tests). Blood samples before treatment and post treatment with erlotinib will be
banked for future serum proteomic analysis. Assessment of response will occur after the
4-week treatment period. Toxicity will be assessed continuously, with patient assessment
weekly on treatment, repeat blood tests at 2 weeks and imaging of measurable disease at 4
weeks. All subjects will be invited to have their initial diagnostic biopsy and subsequent
surgical tumor specimen examined as part of the laboratory correlate component of the study.
Patients will be considered evaluable for pharmacodynamic assessment if they complete at
least 21 of the planned 28 days of therapy.
Patients will have PET-CT scan study done pre- and post-treatment (see section 7). If the
enrolment PET-CT imaging reveals mediastinal disease (IIIA or IIIB) or extensive disease and
this is pathologically confirmed the patient will not be enrolled in the study.
Once the diagnosis is established and assessment completed, oral erlotinib will be
administered at a dose of 150 mg (1 pill) daily for 28 days prior to the planned
mediastinoscopy and/or surgery. Tablets should be taken preferably in the morning with up to
200 mL of water at least 1 hour before or 2 hours after meals. If the patient forgets to take
a dose, they should take the last missed dose as soon as they remember, as long as it is at
least 12 hours before the next dose is due. If patient vomits after taking the dose, the dose
may be retaken if the tablet is seen in the emesis. The last dose of erlotinib will be
administered early in the morning of the mediastinoscopy or surgery.
If the mediastinoscopy reveals the presence of Stage III disease, the patient's
mediastinoscopy samples may still be analyzed as part of the correlative study. Patients will
be followed for 90 days or as long as required after the last dose of erlotinib to ensure
resolution of any erlotinib-related toxicities. However these patients will be offered
standard therapy for stage III disease off study protocol, for example a combination of
chemotherapy, radiation with or without surgical resection. If these patients do proceed to
thoracotomy post-chemotherapy and/or radiotherapy, their resection specimen will not be
eligible for this correlative protocol.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |